Biomarker panels and methods for predicting preeclampsia
AssigneeSera Prognostics, Inc.
InventorsJulja Burchard, Paul Edward Kearney, Md Bahadur Badsha, Ashoka Dharmapriya Polpitiya
Life of this patent
Estimating the term…
Loading patent…
AssigneeSera Prognostics, Inc.
InventorsJulja Burchard, Paul Edward Kearney, Md Bahadur Badsha, Ashoka Dharmapriya Polpitiya
Estimating the term…
The present disclosure provides biomarker panels, methods and kits for determining the probability for preeclampsia in a pregnant female, including preterm preeclampsia or preeclampsia at any gestational age. The disclosure is based, in part, on the discovery that certain proteins and peptides in biological samples obtained from a pregnant female are differentially expressed in pregnant females that have an increased risk of developing, in the future, or presently suffering from, preeclampsia relative to matched controls. The disclosure is also partially based on the unexpected discovery that panels combining one or more of these proteins/peptides can be utilized in methods of determining the probability for preeclampsia in a pregnant female with relatively high sensitivity and specificity. These proteins and peptides disclosed herein serve as biomarkers for classifying test samples, predicting a probability of preeclampsia, monitoring of progress of preeclampsia, either individually or in a panel of biomarkers.
A panel of isolated biomarkers comprising N of the biomarkers listed in Table 1, Table 6, Table 7, Table 8, or Table 9.
A method of determining probability for preterm preeclampsia or preeclampsia at any gestational age in a pregnant female, the method comprising detecting a measurable feature of each of N biomarkers selected from the biomarkers listed in Table 1, Table 6, Table 7, Table 8, or Table 9 in a biological sample obtained from said pregnant female, and analyzing said measurable features to determine the probability for preterm preeclampsia or preeclampsia at any gestational age in said pregnant female.
A method of determining probability for preterm preeclampsia or preeclampsia at any gestational age in a pregnant female, the method comprising:
A kit comprising one or more agents for detection of one or more biomarkers or fragments or derivatives thereof, wherein the one or more biomarkers are selected from the group consisting of AFAM, CD14, LYAM1, IBP4, INHBC, PRG2, ENPP2, PEDF, PAPP1, CBPN, CSH and SHBG.
A kit comprising one or more agents for detection of one or more biomarkers or fragments or derivatives thereof, wherein the one or more biomarkers are selected from the biomarkers listed in Table 1, Table 6, Table 7, Table 8, or Table 9.
A biochip for the detection of one or more biomarkers or fragments or derivatives thereof, wherein the one or more biomarkers are selected from the group consisting of AFAM, CD14, LYAM1, IBP4, INHBC, PRG2, ENPP2, PEDF, PAPP1, CBPN, CSH and SHBG.
A biochip for the detection of one or more biomarkers or fragments or derivatives thereof, wherein the one or more biomarkers are selected from the biomarkers listed in Table 1, Table 6, Table 7, Table 8, or Table 9.
A biomarker for use in determining probability for preterm preeclampsia or preeclampsia at any gestational age in a pregnant female, wherein the biomarker is selected from the group consisting of AFAM, CD14, LYAM1, IBP4, INHBC, PRG2, ENPP2, PEDF, PAPP1, SHBG, CBPN, CSH and the ratio of IBP4 levels to SHBG levels.
A biomarker for use in determining probability for preterm preeclampsia or preeclampsia at any gestational age in a pregnant female, wherein the biomarker is from the biomarkers listed in Table 1, Table 6, Table 7, Table 8, or Table 9.
Use of AFAM, CD14, LYAM1, IBP4, INHBC, PRG2, ENPP2, PEDF, PAPP1, SHBG, CBPN, CSH and/or the ratio of IBP4 levels to SHBG levels, as a biomarker or biomarkers for determining probability for preterm preeclampsia or preeclampsia at any gestational age in a pregnant female.
Use of N biomarkers selected from the biomarkers listed in Table 1, Table 6, Table 7, Table 8, or Table 9 for determining probability for preterm preeclampsia or preeclampsia at any gestational age in a pregnant female, wherein N is a number selected from the group consisting of 2 to 12.
Dependencies are inferred from the claim text.